Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Holdings, Inc. (OTCQX: COSM) announced a further reduction of $1.0 million in related party debt, converting it into 166,667 shares of common stock at $6.00 per share. This transaction follows a previous debt reduction of $3.0 million at the same price. CEO Greg Siokas emphasized the conversion strengthens their balance sheet and supports the company's growth and potential uplisting to the Nasdaq. Cosmos specializes in pharmaceuticals and has a broad EU distribution network, aiming to enhance patient outcomes.

Cosmos Holdings has launched its Sky Premium Life products on Amazon and eBay, with plans for a second phase to include physical stores. The company has entered an exclusive distribution agreement with Mediprovita for distribution in Germany and Austria. Approximately 25 SKUs will be launched in the next two months, with the goal of listing all 65 by year-end. This partnership is poised to enhance revenue and expand the company’s footprint in the European and Asian markets.

Cosmos Holdings (OTCQX: COSM) has appointed finance expert Alexi Papaconstantinou to its Advisory Board. With over 20 years in investment banking, portfolio management, and mergers and acquisitions, his expertise is expected to enhance the company's growth strategy. CEO Greg Siokas highlighted that Papaconstantinou's experience will be crucial for expanding their global reach and achieving a senior national exchange listing. Papaconstantinou expressed enthusiasm about contributing to Cosmos's mission of launching innovative pharmaceutical and nutraceutical products globally.

Cosmos Holdings (OTCQX: COSM) announced a significant move to reduce its debt by converting $3.0 million owed by CEO Greg Siokas into 500,000 shares at a price of $6.00 per share. This conversion was executed on June 25, 2021, and represents a premium to the previous day's closing price. Siokas emphasized the company's commitment to growth, particularly through expanding its pharmaceutical and nutraceutical offerings, enhancing its global distribution network, and elevating its market presence with plans to uplist to the Nasdaq.

Cosmos Holdings (COSM) reported a revenue decline of 2.6% for Q1 2021, totaling $11.6 million, attributed to the pandemic and Brexit's impact on parallel trade. However, the nutraceuticals segment surged by 89% year-over-year. New product launches, including Sky Premium Life items and an antiseptic spray, are expected to bolster revenue. The company aims to enhance visibility through a national securities exchange uplist and continues heavy investments in R&D and marketing. The net loss for the quarter was $2.2 million, translating to a loss of $0.14 per share.

Cosmos Holdings (OTCQX: COSM) has announced the launch of 65 Sky Premium Life products on Amazon UK through its subsidiary, Decahedron Ltd. This move marks a significant step in the company’s e-commerce strategy and aims to capitalize on the growing demand for vitamins and supplements, which saw a 14.3% increase in the UK market in 2020. Cosmos plans to have ten SKUs available next month and aims for full listing by year-end. CEO Greg Siokas emphasized the potential for exponential growth in consumer reliance on online shopping and VMS consumption.

Cosmos Holdings (COSM) reported a 40% revenue increase to $55.4 million for the year ending December 31, 2020, compared to $39.7 million in 2019. Gross profit surged 120% to $8.1 million, with net income rising to $0.8 million, or $0.06 per share, from a loss of $3.3 million in the previous year. The company also improved its working capital position, reporting $6.0 million compared to a deficit of $7.1 million in 2019. CEO Greg Siokas highlighted the robust growth trajectory and expansion plans, expecting to increase their product offerings significantly in 2021.

Cosmos Holdings has launched King Eros and Queen Venus, nutritional supplements aimed at enhancing sexual health for men and women, respectively. These products are being introduced in approximately 1,700 pharmacies in Greece and selected stores in Cyprus, with plans for an additional 1,500 pharmacies by year-end. The company aims for international expansion into the UK, Germany, Canada, and China. Both products are crafted following GMP standards, reflecting quality and safety. CEO Greg Siokas emphasizes strong market demand for these health supplements.

Cosmos Holdings has launched Mosept-Oral, a proprietary oral antiseptic spray targeting bacterial and viral throat infections. Initially available in 3,500 pharmacies in Greece, the company aims to expand to 10,000 pharmacies by year-end. The product contains Chlorhexidine and Lidocaine for sore throat relief and is being registered for sales in various European and Middle Eastern markets. Research suggests its effectiveness against SARS-CoV-2, encouraging potential for broader applications in pandemic health measures.